Canada clears import of J&J COVID-19 vaccine doses made at Emergent plant
Reuters
Published Nov 24, 2021 10:23AM ET
Updated Nov 24, 2021 10:50AM ET
(Reuters) -The Canadian health regulator said on Wednesday it would allow Johnson & Johnson (NYSE:JNJ) to import its COVID-19 vaccine made at contract manufacturer Emergent BioSolutions Inc's plant in the United States.
The decision, Health Canada said, came after it had completed an inspection of the facility in Baltimore, Maryland, along with the European Medicines Agency and South African Health Products Regulatory Authority.
The beleaguered facility has been under regulatory scrutiny since a manufacturing error earlier this year ruined millions of doses of J&J's COVID-19 vaccine.
Canada in June said it would not accept any doses made at the plant until it completed its own on-site inspection.
The three regulators found the facility to be compliant with good manufacturing practices, Health Canada said on Wednesday.
The U.S. Food and Drug Administration in April halted operations at the facility after J&J's vaccine was found to be contaminated with material from AstraZeneca (NASDAQ:AZN)'s COVID-19 shots, which were also being manufactured there at the time.
The FDA's inspection had turned up a long list of problems, including peeling paint, shoddy cleanups, and poorly-trained staff.
Use of many doses of the J&J vaccine made at the Emergent facility is still not cleared by the FDA, although the agency has since cleared uses of batches manufactured prior to the production halt.
The FDA, Emergent, and J&J did not immediately respond to Reuters' request for comment.
Earlier on Wednesday, Canada said it had granted full approval to the J&J vaccine.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.